Literature DB >> 16304411

Acquired disorders of platelet function.

Amy A Hassan1, Michael H Kroll.   

Abstract

A qualitative abnormality of platelet function should be considered in patients with mucocutaneous bleeding in the absence of thrombocytopenia or von Willebrand disease. Antiplatelet drugs are the most common cause of acquired platelet disorders leading to bleeding. Uremia, hepatic cirrhosis, myeloma and related disorders, polycythemia vera, essential thrombocythemia, and cardiopulmonary bypass have long been recognized as clinical situations in which platelet dysfunction may contribute to bleeding. When an acquired platelet disorder is suspected, it is useful to examine platelet function by measuring the bleeding time, examining platelet-dependent closure time in a platelet function analyzer and performing platelet aggregometry. When a specific acquired platelet disorder is diagnosed, many treatment options are available including controlling the underlying disease, giving platelet transfusions and administering a hemostatic drug.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304411     DOI: 10.1182/asheducation-2005.1.403

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  4 in total

Review 1.  Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders.

Authors:  Sujoy Ray; Amita Ray
Journal:  Cochrane Database Syst Rev       Date:  2016-11-10

Review 2.  Acquired hemophilia: a rare but life-threatening potential cause of bleeding in the intensive care unit.

Authors:  Aryeh Shander; Christopher E Walsh; Caroline Cromwell
Journal:  Intensive Care Med       Date:  2011-05-31       Impact factor: 41.787

Review 3.  Clinical Implications of Thrombocytopenia for the Cirrhotic Patient.

Authors:  Samuel H Sigal; Zachary Sherman; Arun Jesudian
Journal:  Hepat Med       Date:  2020-04-14

4.  Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke.

Authors:  Nina A Hilkens; Ale Algra; L Jaap Kappelle; Philip M Bath; László Csiba; Peter M Rothwell; Jacoba P Greving
Journal:  Neurology       Date:  2018-01-26       Impact factor: 9.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.